Fixed-dose combination antihypertensive therapy was associated with 29% fewer hospitalizations (RR 0.721) and 29% fewer emergency department visits (RR 0.712) compared to multi-pill therapy in US adults with hypertension on combination treatment.
Cross-Sectional (n=18,269)
Sí
Does fixed-dose combination antihypertensive therapy reduce healthcare utilization in adults with hypertension compared to multi-pill combination therapy?
Fixed-dose combination antihypertensive therapy is associated with significantly lower acute healthcare utilization and prescription burden compared to multi-pill regimens in US adults.
Estimación del efecto: RR 0.712 for emergency department visits, RR 0.721 for hospitalizations, RR 0.934 for office-based visits, RR 0.853 for prescription fills (95% CI 95% CI 0.636–0.796 for ED visits, 0.545–0.953 for hospitalizations, 0.879–0.993 for office visits, 0.815–0.893 for prescription fills)
valor p: p=<0.0001 for ED visits and prescription fills, 0.0219 for hospitalizations, 0.0281 for office visits
Background Fixed-dose combination (FDC) antihypertensive therapy is recommended by contemporary guidelines to improve adherence and blood pressure control. However, real-world evidence evaluating its impact on healthcare utilization, compared with the multi-pill combination (MPC) therapy in hypertension (HTN) patients, remains limited. This study compared healthcare utilization among US adults with HTN receiving FDC versus MPC therapy. Methods We conducted a cross-sectional study on nationally representative data from the Medical Expenditure Panel Survey (2013-2022). Adults aged ≥18 years with a diagnosed HTN on ≥2 antihypertensive classes were classified as FDC or MPC users. Inverse probability of treatment weighting was applied to balance covariates. Weighted negative binomial regression models were used to assess the impact of FDC versus MPC on healthcare utilization, including office-based visits, outpatient visits, emergency department visits, hospitalizations, and prescription fills. A 1:1 propensity score matching (PSM) analysis was conducted as a sensitivity analysis to assess findings robustness. Results Among 18,269 adults receiving ≥2 antihypertensive therapies, 5,849 were FDC users, and 12,420 were MPC users. Compared with MPC users, FDC users had significantly lower emergency department visits (rate ratio RR = 0.712; 95% confidence interval CI: 0.636–0.796; p 0.0001), hospitalizations (RR = 0.721; 95% CI: 0.545–0.953; p = 0.0219), office-based visits (RR = 0.934; 95% CI: 0.879–0.993; p 0.0281), and prescription fills (RR = 0.853; 95% CI: 0.815–0.893; p 0.0001). No significant difference was observed in the outpatient visit rate. Findings were consistent in PSM analysis. Conclusion FDC antihypertensive therapy was associated with significantly lower acute care utilization and prescription burden while preserving routine outpatient care, compared with the MPC therapy. These findings support FDC therapy use as a high-value strategy to enhance real-world HTN management and reduce acute healthcare utilization.
Eissa A. Jafari (Fri,) conducted a cross-sectional in U.S. adults aged ≥18 years with diagnosed hypertension on combination antihypertensive therapy of ≥2 drug classes (n=18,269). Fixed-dose combination (FDC) antihypertensive therapy vs. Multi-pill combination (MPC) antihypertensive therapy was evaluated on Annual healthcare utilization including office-based visits, outpatient visits, emergency department visits, hospitalizations, and prescription fills (RR 0.712 for emergency department visits, RR 0.721 for hospitalizations, RR 0.934 for office-based visits, RR 0.853 for prescription fills, 95% CI 95% CI 0.636–0.796 for ED visits, 0.545–0.953 for hospitalizations, 0.879–0.993 for office visits, 0.815–0.893 for prescription fills, p=<0.0001 for ED visits and prescription fills, 0.0219 for hospitalizations, 0.0281 for office visits). Fixed-dose combination antihypertensive therapy was associated with 29% fewer hospitalizations (RR 0.721) and 29% fewer emergency department visits (RR 0.712) compared to multi-pill therapy in US adults with hypertension on combination treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: